Atrandi

Scalable single-cell research platform

Vilnius, Lithuania

Atrandi is a precision medicine platform.

Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.

Get Involved in Atrandi

Claim This Profile →

How We Help

Problem Statement

Current single-cell analysis methods limit scientific discovery and the development of new therapies.

Core Technology

microfluidics

Key Differentiators

Pioneering next-generation single-cell analysis technology; Semi-permeable capsule (SPC) technology

Clinical Focus

Oncology; Cell Therapy

Company Info

Business Model: Device Sales
Founded: 2016
Total Funding: 25,000,000
Website: atrandi.com/

Disease Areas

Oncology Age-Related Diseases

Technologies

microfluidicslife sciences tools

Clinical & IP

🔬

Clinical Validation

Published in Frontiers in Microbiology (2024) on high-throughput microbial sequencing. Used in Harvard Medical School research (Science publication). 150+ installations globally supporting eukaryotic/microbial genomics and high-throughput screening.

🌐Website

MedStartr Index Score

What do you think of Atrandi?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.